Cargando…

Exploiting innate immunity for cancer immunotherapy

Immunotherapies have revolutionized the treatment paradigms of various types of cancers. However, most of these immunomodulatory strategies focus on harnessing adaptive immunity, mainly by inhibiting immunosuppressive signaling with immune checkpoint blockade, or enhancing immunostimulatory signalin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yi, Ming, Li, Tianye, Niu, Mengke, Mei, Qi, Zhao, Bin, Chu, Qian, Dai, Zhijun, Wu, Kongming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680233/ https://www.ncbi.nlm.nih.gov/pubmed/38008741 http://dx.doi.org/10.1186/s12943-023-01885-w

Ejemplares similares

Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy
por: Li, Tianye, et al.
Publicado: (2023)

Epidemiological trends of women’s cancers from 1990 to 2019 at the global, regional, and national levels: a population-based study
por: Yi, Ming, et al.
Publicado: (2021)

Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy
por: Wu, Yuze, et al.
Publicado: (2022)

TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy
por: Yi, Ming, et al.
Publicado: (2022)

Increased expression of ECT2 predicts the poor prognosis of breast cancer patients
por: Yi, Ming, et al.
Publicado: (2022)

Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers
por: Yi, Ming, et al.
Publicado: (2021)

Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy
por: Li, Anping, et al.
Publicado: (2019)

Manipulating Gut Microbiota Composition to Enhance the Therapeutic Effect of Cancer Immunotherapy
por: Yi, Ming, et al.
Publicado: (2019)

Immunotherapies: Exploiting the Immune System for Cancer Treatment
por: Koury, Jeffrey, et al.
Publicado: (2018)

Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer
por: Yi, Ming, et al.
Publicado: (2022)

Intratumoral cancer immunotherapy exploiting anti-viral immunity
por: Kadowaki, Norimitsu
Publicado: (2021)

Upregulation of STAT1-CCL5 axis is a biomarker of colon cancer and promotes the proliferation of colon cancer cells
por: Niu, Mengke, et al.
Publicado: (2020)

Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
por: Niu, Mengke, et al.
Publicado: (2022)

The roles of ERIANIN in tumor and innate immunity and its’ perspectives in immunotherapy
por: Yang, Zhen, et al.
Publicado: (2023)

Identifying Tumorigenesis and Prognosis-Related Genes of Lung Adenocarcinoma: Based on Weighted Gene Coexpression Network Analysis
por: Yi, Ming, et al.
Publicado: (2020)

Nanomaterials for modulating innate immune cells in cancer immunotherapy
por: Le, Quoc-Viet, et al.
Publicado: (2019)

Innate immunity and immunotherapy for hemorrhagic shock
por: Huang, Qingxia, et al.
Publicado: (2022)

Immune pressures drive the promoter hypermethylation of neoantigen genes
por: Yi, Ming, et al.
Publicado: (2019)

Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
por: Yi, Ming, et al.
Publicado: (2022)

Advances of Targeted Therapy for Hepatocellular Carcinoma
por: Niu, Mengke, et al.
Publicado: (2021)

Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy
por: Niu, Mengke, et al.
Publicado: (2023)

Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
por: Yi, Ming, et al.
Publicado: (2019)

The role of neoantigen in immune checkpoint blockade therapy
por: Yi, Ming, et al.
Publicado: (2018)

Cancer Immunotherapy by Blocking Immune Checkpoints on Innate Lymphocytes
por: Pesce, Silvia, et al.
Publicado: (2020)

Regulation of PD-L1 expression in the tumor microenvironment
por: Yi, Ming, et al.
Publicado: (2021)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
por: Niu, Mengke, et al.
Publicado: (2021)

Targeting Innate Immune Cells for Immunotherapy
por: Carreño, Leandro J., et al.
Publicado: (2017)

Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways
por: Li, Kai, et al.
Publicado: (2017)

Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor
por: Bai, Xianguang, et al.
Publicado: (2019)

Immune signature-based risk stratification and prediction of immune checkpoint inhibitor’s efficacy for lung adenocarcinoma
por: Yi, Ming, et al.
Publicado: (2021)

Chronic stress boosts systemic inflammation and compromises antiviral innate immunity in Carassius gibel
por: Dai, Caijiao, et al.
Publicado: (2023)

Innate Immune Mechanisms and Immunotherapy of Myeloid Malignancies
por: Small, Sara, et al.
Publicado: (2021)

Gut microbiome modulates efficacy of immune checkpoint inhibitors
por: Yi, Ming, et al.
Publicado: (2018)

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
por: Yi, Ming, et al.
Publicado: (2022)

Prospects for combining immune checkpoint blockade with PARP inhibition
por: Li, Anping, et al.
Publicado: (2019)

Inflammasome Signaling: A Novel Paradigm of Hub Platform in Innate Immunity for Cancer Immunology and Immunotherapy
por: Li, Ying, et al.
Publicado: (2021)

Cancer immunotherapy: Re-programming cells of the innate and adaptive immune systems
por: Manjili, Masoud H., et al.
Publicado: (2012)

Activation of innate and adaptive immunity as an effective combined strategy for cancer immunotherapy
por: Rakhmilevich, Alexander, et al.
Publicado: (2015)

The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy
por: Law, Andrew M K, et al.
Publicado: (2017)

Innate Immune Defense Mechanisms by Myeloid Cells That Hamper Cancer Immunotherapy
por: Lebegge, Els, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bhr8huj54b44pdfoep2rq4b6u2